Enterprise Value
-1.713M
Cash
7.079M
Avg Qtr Burn
-8.201M
Short % of Float
3.70%
Insider Ownership
0.02%
Institutional Own.
16.65%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AL102 Details Benign tumor, Genetic disorder, Achromatopsia | Phase 2 Data readout | |
AL101 Details Carcinoma , Salivary gland carcinoma , Salivary gland, Cancer | Phase 2 Data readout | |
ADXS- 504 Details Cancer, Prostate cancer | Phase 1 Data readout | |
AL101 Details Leukemia, Acute lymphoblastic leukemia | Failed Discontinued | |
AL101 Details Breast cancer, Cancer | Failed Discontinued |